Company intelligence / Profile preview

ReCyte Therapeutics

Alameda, California, United States

Ownership: Private
Development stage: Other

Overview

ReCyte Therapeutics has demonstrated successful isolation of novel pericyte-like progenitor cells from human embryonic stem cells. These cells show promise in preclinical models for restoring blood flow in ischemic diseases, and the company has also developed an angiogenesis drug screening assay; no clinical-stage data reported to date.

Therapeutic areas: Cardiovascular
Modalities: Induced pluripotent stem cell derived therapyEmbryonic stem cell derived therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

fallopian tube pericytes

Preclinical

Partnerships

Ascendance Biotechnology (distribution of VascuNet assay)

Beyond the preview

Go deeper on ReCyte Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReCyte Therapeutics.

Explore the full profile